Search Results

Corporate

January 6, 2020

Dr. Paul Janssen Award for Biomedical Research Issues 2020 Call for Nominations to Celebrate Champions of Science

December 10, 2019

DARZALEX® (Daratumumab) Regimen Shows Significant Increase in Progression-Free Survival in Treatment of Patients with Relapsed/Refractory Multiple Myeloma

· First Phase 3 study showing addition of the CD38-directed antibody DARZALEX® to carfilzomib in combination with dexamethasone · Data selected as a Late-Breaking Abstract at ASH 2019

Innovative Medicine

December 9, 2019

Janssen to Acquire Investigational Bermekimab from XBiotech

Clinical Stage, First-in-Class Anti-IL-1a Antibody for Atopic Dermatitis and Hidradenitis Suppurativa

Innovative Medicine

December 9, 2019

Janssen Announces BCMA CAR-T Therapy JNJ-4528 Granted U.S. FDA Breakthrough Therapy Designation for the Treatment of Relapsed or Refractory Multiple Myeloma

Newest designation for JNJ-4528 is supported by Phase 1b/2 CARTITUDE-1 study in adults with relapsed or refractory multiple myeloma Initial results from CARTITUDE-1 study to premiere at the American Society of Hematology Annual Meeting

Global health equity

December 8, 2019

Johnson & Johnson Announces Commitment to Support Republic of Rwanda’s Preparedness Against Ebola Outbreak

Up to 200,000 Regimens of Janssen’s Investigational Ebola Vaccine to be Supplied to Rwanda for Use in Border Region near Democratic Republic of the Congo (DRC)

Innovative Medicine

December 2, 2019

Johnson & Johnson Announces Winners of Champions of Science® Storytelling Challenge – Latin America and the Caribbean Edition

Program Spotlights Scientific Contributions and Personal Journeys of Scientists Across the Region

Innovative Medicine

November 12, 2019

New Analysis from Landmark CREDENCE Study Shows the Efficacy and Safety Profiles of INVOKANA® (canagliflozin) are Consistent Across Various Levels of Kidney Function

Analysis shows consistent renal and cardiovascular benefit when treated with INVOKANA® even when patients had moderate to severe renal deficiency INVOKANA® is the only diabetes medicine indicated to slow the progression of diabetic nephropathy (also known as DKD) and reduce the risk of hospitalization for heart failure in patients with type 2 diabetes (T2D) and DKD Data announcement comes after recent news of the company’s commercial partnership with Vifor Pharma, leader in nephrology, to jointly commercialize the INVOKANA® DKD indication in the United States

Innovative Medicine

November 11, 2019

TREMFYA® (guselkumab), a First-in-Class IL-23 p19 Subunit Inhibitor, Meets Primary Endpoints of Superior ACR20 Responses versus Placebo at Week 24 in Phase 3 Psoriatic Arthritis Studies

Findings from the DISCOVER-1 and DISCOVER-2 studies are presented, for the first time, at the 2019 American College of Rheumatology and Association of Rheumatology Professionals Annual Meeting These are the first Phase 3 results evaluating p19-specific IL-23 inhibition in active psoriatic arthritis

Global health equity

November 7, 2019

Johnson & Johnson Announces Submission of European Marketing Authorisation Applications for Janssen’s Investigational Ebola Vaccine Regimen

Data from multiple preclinical, Phase 1, 2 and 3 studies support applications, which have been granted Accelerated Assessment by European Medicines Agency

Global health equity

October 31, 2019

Johnson & Johnson Announces Donation of up to 500,000 Regimens of Janssen’s Investigational Ebola Vaccine to Support Outbreak Response in Democratic Republic of the Congo (DRC)

The government of the DRC supports use of Janssen’s vaccine regimen as part of expanded public health response to country’s Ebola outbreak – the second-worst on record

Search Results

No Results

Search Results

You are now leaving jnj.com/innovativemedicine